$AMRI (Albany Molecular Research Inc.)

$AMRI {{ '2016-05-10T16:48:36+0000' | timeago}} • Announcement

$AMRI said it expects approx. 50% of its 2016 revenue to be realized in the first half of the year and the corresponding 50% in the second half of the year, respectively. It expects about 40% of its 2016 adj. earnings per share to be realized in the first half of the year, and the corresponding 60% in the second half of the year.

$HUM {{ '2018-01-16T20:57:20+0000' | timeago}} • Announcement

Healthcare company $HUM has appointed Luis Torres Olivera as President, Health and Well-being, for the Puerto Rico Market. Torres Olivera, who joined the company more than a decade ago, has overseen several key projects. He succeeds Earl Harper, who will be retiring at the end of February 2018.

$MDT {{ '2018-01-16T17:16:57+0000' | timeago}} • Announcement

$MDT received FDA clearance of the Riptide Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. This is designed to retrieve thrombus (or blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke.

$CRL {{ '2018-01-16T14:14:39+0000' | timeago}} • Announcement

$CRL appointed Jean-Paul Mangeolle, former President of AB SCIEX, to its BoD. As a member of the Board, he will serve on the Audit and Compensation Committees.

$CRL {{ '2018-01-11T13:12:01+0000' | timeago}} • Announcement

Drug research solutions provider $CRL has acquired KWS BioTest, a contract research organization, for about $20MM. The deal also includes a potential additional payment of up to $4MM based on future performance. The acquisition is not expected to be material to Charles River’s GAAP or non-GAAP results from operations this year.

$DEPO {{ '2018-01-10T17:44:57+0000' | timeago}} • Announcement

$DEPO announced the closing of its Commercialization Agreement for the US rights to commercialize both NUCYNTA Extended Release and NUCYNTA Immediate Release with Collegium Pharmaceutical Inc. In connection with the closing, $DEPO received an upfront $10MM cash payment from Collegium.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$SEM {{ '2018-01-09T18:17:01+0000' | timeago}} • Announcement

$SEM announced a JV agreement with Banner Health to combine operations of more than 38 physical therapy centers in Arizona and four acute inpatient rehabilitation hospitals in Phoenix. Banner Health will be the majority owner and $SEM will serve as managing partner.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$SEM {{ '2018-01-08T18:16:59+0000' | timeago}} • Announcement

$SEM expects consolidated net operating revenues for full year 2018 to be $5-5.2Bil. Adjusted EBITDA is expected to be $630-660MM. $SEM expects fully diluted income per common share for full year 2018 to be $0.97-1.12.

$MLNT {{ '2018-01-08T17:08:01+0000' | timeago}} • Announcement

$MLNT completed the acquisition of $MDCO’s infectious disease business. $MLNT also announced that $MDCO’s Mike McGuire has joined the new organization as SVP, Commercial, replacing Chief Commercial Officer, John Temperato, who left $MLNT to pursue other opportunities.

$MDCO {{ '2018-01-08T13:17:52+0000' | timeago}} • Announcement

Pharma firm $MDCO closed the sale of its infectious disease business to $MLNT for $215MM of guaranteed cash and 3.3 MM common shares of Melinta. The sale consideration also includes royalty payments of 5-25% on certain drug sales and the assumption by Melinta of all royalty, milestone and other payment obligations relating to those products.

$OSUR {{ '2018-01-04T13:33:43+0000' | timeago}} • Announcement

Diagnostic devices maker $OSUR has named Stephen Tang President and CEO, effective April 1, 2018, to succeed Douglas Michels who will be retiring in March. Tang will step down as Chairman, but continue as a Director. Meanwhile, Ronald Spair will retire as CFO and COO later this year. Further, OraSure revised up its 4Q17 revenue guidance to $50MM.

$MYGN {{ '2018-01-03T13:32:07+0000' | timeago}} • Announcement

$MYGN said $AZN will use its myChoice HRD Plus test in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza & Avastin. Under the agreement, $MYGN will use its myChoice Plus test to evaluate patients enrolled in an ongoing Phase III trial. Financial terms were not disclosed.

$ACET {{ '2018-01-02T20:11:33+0000' | timeago}} • Announcement

$ACET's finished dosage form generics subsidiary Rising Pharmaceuticals launched the first generic for Efavirenz Capsules. This is an FDA-approved generic version of the reference listed drug, Sustiva from $BMY, which in combination with other drugs is indicated for the treatment of HIV-1 infection in adults and pediatric patients.

$JNJ {{ '2018-01-02T19:20:09+0000' | timeago}} • Announcement

$JNJ declared a cash dividend for 1Q18 of $0.84 per share on the company's common stock. The dividend is payable on March 13, 2018 to shareholders as on Feb 27, 2018.

$HLS {{ '2018-01-02T16:09:27+0000' | timeago}} • Announcement

$HLS completed its planned name change to Encompass Health Corp. Effective with the opening of trading on Jan. 2, 2018, the company's NYSE ticker symbol will change from "HLS" to "EHC". The rollout is expected to be fully completed by 1Q19.

$JNJ {{ '2017-12-21T18:10:50+0000' | timeago}} • Announcement

Janssen Biotech, a $JNJ company, said the FDA has granted Priority Review designation for the New Drug Application (NDA) for apalutamide as treatment for non-metastatic castration-resistant prostate cancer (CRPC). This is the first agent submitted for approval to treat earlier stage castration-resistant prostate cancer at high risk for metastasis.

$HUM {{ '2017-12-19T15:27:46+0000' | timeago}} • Announcement

$HUM signed a definitive agreement to acquire a 40% minority interest in the Kindred at Home Division of $KND for an estimated cash consideration of approximately $800MM. Humana does not anticipate a material impact to earnings in 2017 from this pending transaction.

$ZBH {{ '2017-12-19T14:31:26+0000' | timeago}} • Announcement

$ZBH appointed Bryan Hanson as President and CEO and a member of the BoD, effective Dec. 19, 2017. Daniel Florin, who has served as Interim CEO since July 11, 2017, will continue in his role as SVP and CFO. Most recently, Hanson served as a $MDT's Executive Committee member and as EVP and President of Medtronic's Minimally Invasive Therapies Group.

$MDT {{ '2017-12-19T14:11:39+0000' | timeago}} • Announcement

$MDT has named Bob White, previously SVP and President of APAC Region, as EVP and President of Minimally Invasive Therapies Group. The company also announced Chris Lee, SVP and President of Greater China Region, will assume the position of APAC Region President. These leadership changes are effective immediately.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
XON (Intrexon Corporation)
Thursday, November 9 2017 - 10:30pm
CRL (Charles River Laboratories International, Inc.)
Thursday, November 9 2017 - 1:30pm
HUM (Humana Inc.)
Wednesday, November 8 2017 - 2:00pm
IVC (Invacare Corporation)
Wednesday, November 8 2017 - 1:30pm
DEPO (DepoMed Inc.)
Tuesday, November 7 2017 - 9:30pm
CBM (Cambrex Corporation.)
Tuesday, November 7 2017 - 1:30pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
CAH (Cardinal Health, Inc.)
Monday, November 6 2017 - 1:30pm
ACET (Aceto Corp.)
Friday, November 3 2017 - 1:00pm
SEM (Select Medical Holdings Corporation)
Friday, November 3 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
HLF (Herbalife Ltd.)
Thursday, November 2 2017 - 9:30pm
SNMX (Senomyx Inc.)
Thursday, November 2 2017 - 9:00pm
EXEL (Exelixis, Inc.)
Wednesday, November 1 2017 - 9:00pm
OSUR (OraSure Technologies, Inc.)
Wednesday, November 1 2017 - 9:00pm
HCA (HCA Holdings, Inc.)
Tuesday, October 31 2017 - 2:00pm
INCY (Incyte Corporation)
Tuesday, October 31 2017 - 2:00pm
EXAS (Exact Sciences Corporation)
Monday, October 30 2017 - 9:00pm
HLS (HEALTHSOUTH Corp.)
Friday, October 27 2017 - 1:00pm

AlphaGraphics you may like